External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Abstract

Summary Background The International Metastatic Renal-Cell Carcinoma Database Consortium model offers prognostic information for patients with metastatic renal-cell carcinoma. We tested the accuracy of the model in an external population and compared it with other prognostic models. Methods We included patients with metastatic renal-cell carcinoma who were treated with first-line VEGF-targeted treatment at 13 international cancer centres and who were registered in the Consortium’s database but had not contributed to the initial development of the Consortium Database model. The primary endpoint was overall survival. We compared the Database Consortium model with the Cleveland Clinic Foundation (CCF) model, the International Kidney Cancer Working Group (IKCWG) model, the French model, and the Memorial Sloan-Kettering Cancer Center (MSKCC) model by concordance indices and other measures of model fit. Findings Overall, 1028 patients were included in this study, of whom 849 had complete data to assess the Database Consortium model. Median overall survival was 18·8 months (95% 17·6–21·4). The predefined Database Consortium risk factors (anaemia, thrombocytosis, neutrophilia, hypercalcaemia, Karnofsky performance status <80%, and <1 year from diagnosis to treatment) were independent predictors of poor overall survival in the external validation set (hazard ratios ranged between 1·27 and 2·08, concordance index 0·71, 95% CI 0·68–0·73). When patients were segregated into three risk categories, median overall survival was 43·2 months (95% CI 31·4–50·1) in the favourable risk group (no risk factors; 157 patients), 22·5 months (18·7–25·1) in the intermediate risk group (one to two risk factors; 440 patients), and 7·8 months (6·5–9·7) in the poor risk group (three or more risk factors; 252 patients; p<0·0001; concordance index 0·664, 95% CI 0·639–0·689). 672 patients had complete data to test all five models. The concordance index of the CCF model was 0·662 (95% CI 0·636–0·687), of the French model 0·640 (0·614–0·665), of the IKCWG model 0·668 (0·645–0·692), and of the MSKCC model 0·657 (0·632–0·682). The reported versus predicted number of deaths at 2 years was most similar in the Database Consortium model compared with the other models. Interpretation The Database Consortium model is now externally validated and can be applied to stratify patients by risk in clinical trials and to counsel patients about prognosis.

Local treatments for metastases of renal cell carcinoma: a systematic review

“…25,27 For patients receiving targeted treatment, the MSKCC score and the validated Database Consortium model share concordance indices of 0·66-0·65 to assess prognosis. 8,45,46 In one of the studies included in the systematic review, a more favourable risk category and metastasectomy were each independently associated with better survival. 27 However, this may be because, with a median survival of 6 months for poor-risk patients, these patients do not live long enough to derive benefi t from metastasectomy.…”

“…[5][6][7] Data from a population-based analysis suggest that median overall survival plateaus at 9-40 months, depending on patients' clinical risk scores. 8 Therefore, with the exception of rare but durable responses after high-dose interleukin 2, removal of all synchronous or metachronous lesions, when technically feasible and clinically appropriate, provides the only potentially curative treatment alternative. However, the benefi ts of local therapeutic options for metastases from renal cell carcinoma are controversial.…”

Targeted therapy in patients with poor-prognosis renal cell carcinoma

“…При сравнении эффективно-сти монотерапии темсиролимусом у пациентов со светлоклеточными и несветлоклеточными вариан-тами, а также у больных, которым выполняли [6][7][8] …”

“…В соответствии с критериями MSKCC около 20 % больных мПКР относятся к груп-пе неблагоприятного прогноза. Если оценить эту же группу пациентов согласно критериям Heng, то уже 30 % будут отнесены к неблагоприятному прогнозу [6][7][8][9][10].…”

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients

“…However, the efficacy and safety of targeted therapies such as sunitinib in this population is less clear (3). Recently published data suggests that at least 30% of mRCC patients receiving VEGF pathway inhibitors belong to the poor-risk group based on the International Database Consortium (IDC) prognostic model (4). Therefore, we performed a retrospective analysis to evaluate the efficacy, safety and treatment patterns of sunitinib in a non-selected population of poor-risk mRCC patients.…”